Symptoms of Myelodysplastic Syndrome (MDS)

Symptoms of MDS vary depending on the type and severity of the disorder. Many symptoms are related to low blood counts (cytopenias) caused by the bone marrow’s inability to produce enough healthy blood cells.

1. Symptoms of Anemia (Low Red Blood Cells)

• Fatigue or tiredness.
• Weakness.
• Shortness of breath, especially during physical activity.
• Pale skin (pallor).
• Dizziness or lightheadedness.
• Chest pain (in severe cases).

2. Symptoms of Neutropenia (Low White Blood Cells)

• Frequent infections, such as colds, pneumonia, or urinary tract infections.
• Fever.
• Slow recovery from infections.

3. Symptoms of Thrombocytopenia (Low Platelets)

• Easy bruising.
• Unexplained or prolonged bleeding (e.g., from gums, nosebleeds).
• Petechiae (small red or purple spots under the skin caused by bleeding).
• Heavy menstrual periods (in women).

4. General Symptoms

• Unexplained weight loss.
• Loss of appetite.
• Night sweats.
• Bone pain (rare).

When to See a Doctor

If you experience persistent fatigue, frequent infections, unusual bleeding, or other concerning symptoms, it is essential to consult a doctor for evaluation. Early diagnosis of MDS allows for better management of the condition.

Types of Myelodysplastic Syndrome (MDS)

MDS is classified into different subtypes based on factors such as the number of affected blood cell types, the percentage of immature cells (blasts) in the bone marrow, and specific genetic or chromosomal abnormalities. These subtypes are categorized according to the World Health Organization (WHO) classification.

1. MDS with Single Lineage Dysplasia (MDS-SLD)

• Description: Only one type of blood cell (red blood cells, white blood cells, or platelets) is abnormally low and shows dysplasia (abnormal appearance or function).
• Blast Count: Less than 5% in the bone marrow.
• Prognosis: Generally better compared to other MDS types.

2. MDS with Multilineage Dysplasia (MDS-MLD)

• Description: Two or more types of blood cells are affected and show dysplasia.
• Blast Count: Less than 5% in the bone marrow.
• Prognosis: Worse than MDS-SLD due to the involvement of multiple blood cell lines.

3. MDS with Ring Sideroblasts (MDS-RS)

• Description: Abnormal red blood cells contain ring-shaped iron deposits in the mitochondria (ring sideroblasts).
• Subtypes:
  • MDS-RS-SLD: Involves only one blood cell type with dysplasia.
  • MDS-RS-MLD: Involves multiple blood cell types with dysplasia.
• Blast Count: Less than 5% in the bone marrow.
• Prognosis: Moderate; depends on other factors.

4. MDS with Excess Blasts (MDS-EB)

• Description: A higher percentage of immature cells (blasts) in the bone marrow or blood.
• Subtypes:
  • MDS-EB-1: 5-9% blasts in the bone marrow or 2-4% blasts in the blood.
  • MDS-EB-2: 10-19% blasts in the bone marrow or 5-19% blasts in the blood.
• Prognosis: High risk of progression to acute myeloid leukemia (AML).

5. MDS with Isolated del(5q)

• Description: Characterized by a specific chromosomal abnormality, deletion of part of chromosome 5 (del(5q)).
• Blast Count: Less than 5% in the bone marrow.
• Prognosis: Often associated with better outcomes and response to treatments like lenalidomide.

6. MDS, Unclassifiable (MDS-U)

• Description: Does not fit into other categories but shows clear evidence of MDS, such as low blood counts and abnormal cells.
• Blast Count: Less than 5% in the bone marrow.
• Prognosis: Variable, depending on specific features.

Prognostic Factors

• Blast Percentage: Higher blast counts indicate a greater risk of progression to AML.
• Cytogenetics: Certain chromosomal abnormalities, like del(5q), are associated with better outcomes, while others indicate a higher risk.
• Blood Cell Levels: The severity of anemia, neutropenia, or thrombocytopenia influences prognosis.

Summary

The classification of MDS helps doctors determine the severity of the disease and guide treatment decisions. Patients with lower-risk subtypes, such as MDS-SLD or MDS with isolated del(5q), may have better outcomes, while those with higher-risk subtypes, such as MDS-EB, are more likely to progress to acute myeloid leukemia.

Treatment of Myelodysplastic Syndrome (MDS)

The treatment of MDS depends on factors such as the subtype of MDS, the severity of symptoms, the patient’s age, overall health, and the risk of progression to acute myeloid leukemia (AML). The primary goals of treatment are to manage symptoms, improve blood cell counts, reduce the need for transfusions, and prevent disease progression.

1. Supportive Care

This is the most common treatment for low-risk MDS to manage symptoms and improve quality of life.

1. Blood Transfusions

• Red Blood Cell Transfusions: To treat anemia and reduce fatigue.
• Platelet Transfusions: To manage bleeding and reduce the risk of hemorrhage.

1. Iron Chelation Therapy

• Used to remove excess iron from the body caused by frequent blood transfusions.
• Common drugs: Deferasirox (Exjade) or Deferoxamine (Desferal).

1. Growth Factors

• Medications to stimulate the bone marrow to produce more healthy blood cells:
  • Erythropoiesis-Stimulating Agents (ESAs): Such as Epoetin alfa (Procrit) or Darbepoetin alfa (Aranesp) to increase red blood cell production.
  • Granulocyte-Colony Stimulating Factors (G-CSFs): Such as Filgrastim (Neupogen) to boost white blood cell production.

2. Drug Therapy

For patients with intermediate- or high-risk MDS, drugs may be used to control abnormal bone marrow activity.

1. Hypomethylating Agents

• These drugs modify the DNA of abnormal cells to slow their growth or kill them.
• Common options:
  • Azacitidine (Vidaza)
  • Decitabine (Dacogen)
• These are often first-line treatments for higher-risk MDS and can reduce the risk of progression to AML.

1. Immunomodulatory Drugs

• Drugs that help the immune system destroy abnormal cells.
• Lenalidomide (Revlimid):
  • Especially effective for patients with the del(5q) chromosomal abnormality.
  • Improves red blood cell counts and reduces transfusion needs.

1. Targeted Therapies

• Newer drugs that specifically target genetic mutations or cellular pathways in MDS.
• Examples:
  • Venetoclax (Venclexta): Often combined with hypomethylating agents for higher-risk MDS.
  • Luspatercept (Reblozyl): Treats anemia in patients with ring sideroblasts.

3. Stem Cell Transplantation (Bone Marrow Transplant)

• What it is: A procedure to replace diseased bone marrow with healthy stem cells from a donor.
• When used:
  • Often the only potential cure for MDS.
  • Recommended for younger or healthier patients with high-risk MDS or those who have failed other treatments.
• Risks:
  • Can be associated with significant complications, including graft-versus-host disease (GVHD) and infections.

4. Clinical Trials

• Patients with advanced or high-risk MDS may benefit from participating in clinical trials testing new drugs or therapies.
• Ongoing research includes CAR T-cell therapy, bispecific antibodies, and novel targeted treatments.

5. Treatment by Risk Level

Treatment plans are often tailored based on the International Prognostic Scoring System (IPSS), which evaluates the risk of progression to AML.

1. Low-Risk MDS

• Focus on managing anemia and maintaining quality of life.
• Common treatments:
  • ESAs (e.g., epoetin alfa, darbepoetin alfa).
  • Lenalidomide for patients with del(5q).
  • Transfusions and iron chelation therapy if needed.

1. Intermediate- and High-Risk MDS

• Focus on slowing disease progression and preventing transformation to AML.
• Common treatments:
  • Hypomethylating agents (azacitidine, decitabine).
  • Stem cell transplantation for eligible patients.
  • Combination therapies in clinical trials.

6. Supportive and Symptom Management

• Antibiotics and Antifungals: To prevent or treat infections, especially in patients with neutropenia.
• Pain Management: For bone pain or discomfort related to treatments.
• Lifestyle Changes: Maintaining a balanced diet, avoiding infections, and reducing stress can help manage symptoms.

Outlook and Prognosis

• Lower-Risk MDS: Many patients can live with good quality of life for years with supportive care and appropriate treatments.
• Higher-Risk MDS: Requires aggressive treatment to delay progression to AML and manage symptoms effectively.

Consult a hematologist to develop a treatment plan tailored to your specific MDS subtype, overall health, and risk level.

Prevention of Myelodysplastic Syndrome (MDS)

There is no guaranteed way to prevent Myelodysplastic Syndrome (MDS), as the exact cause of the condition is often unknown. However, reducing exposure to known risk factors and maintaining a healthy lifestyle may help lower the risk.

Avoid Exposure to Harmful Chemicals

• Why it matters: Long-term exposure to certain chemicals, such as benzene (found in industrial settings and gasoline), is linked to an increased risk of MDS.
• What to do:
  • Follow safety protocols and use protective gear in workplaces with chemical exposure.
  • Avoid unnecessary exposure to pesticides, herbicides, and solvents.
  •  
• Limit Exposure to Radiation
• Why it matters: High doses of radiation can damage bone marrow cells, increasing the risk of MDS.
• What to do:
  • Avoid unnecessary medical imaging, such as X-rays and CT scans, unless medically necessary.
  • Follow safety guidelines if you work in environments with radiation exposure.
  •  

Avoid Smoking

• Why it matters: Smoking introduces harmful chemicals into the bloodstream that may damage bone marrow and increase cancer risk, including MDS.
• What to do:
  • Quit smoking if you are a smoker.
  • Avoid exposure to secondhand smoke.
  •  

Manage and Minimize Chemotherapy Risk

• Why it matters: Certain chemotherapy drugs used to treat other cancers can increase the risk of secondary MDS.
• What to do:
  • Discuss the risks and benefits of chemotherapy with your doctor if you have cancer.
  • Explore alternative therapies when appropriate.
  •  

Maintain a Healthy Lifestyle

• Why it matters: A strong immune system and healthy cells may lower the risk of bone marrow disorders.
• What to do:
  • Eat a balanced diet rich in fruits, vegetables, lean proteins, and whole grains.
  • Exercise regularly to boost immune function and overall health.
  • Stay hydrated and maintain a healthy weight.
  •  

Avoid Known Risk Factors for Infections

• Why it matters: Chronic infections and inflammation can weaken the immune system and increase cancer risk.
• What to do:
  • Practice good hygiene, such as washing hands frequently.
  • Stay up to date on vaccinations to prevent infections.
  •  

Monitor Genetic Risk Factors

• Why it matters: Some genetic conditions or family histories may predispose individuals to MDS.
• What to do:
  • If you have a family history of blood disorders or cancers, consult a doctor about genetic testing.
  • Regular health screenings may help detect abnormalities early.
  •  

Avoid or Limit Alcohol

• Why it matters: Excessive alcohol consumption may suppress bone marrow function over time.
• What to do:
  • Consume alcohol in moderation or avoid it entirely.
  •  

Seek Regular Medical Check-Ups

• Why it matters: Early detection of abnormal blood cell counts or bone marrow issues can prevent progression to MDS.
• What to do:
  • Schedule routine blood tests, especially if you are in a high-risk group (e.g., history of chemotherapy, radiation exposure).

Conclusion

While MDS cannot always be prevented, reducing exposure to harmful chemicals, radiation, and smoking, along with adopting a healthy lifestyle, can help lower the risk. If you are at higher risk due to genetics or previous cancer treatments, regular medical check-ups and discussions with your healthcare provider are essential for early detection and prevention strategies.

NEWER ADVANCMENTS AND RESEARCHES IN MDS

Recent advancements in the treatment of Myelodysplastic Syndromes (MDS) have led to the development and approval of new therapies, offering hope for improved patient outcomes.

1. FDA Approval of Ivosidenib (Tibsovo): In May 2024, the U.S. Food and Drug Administration (FDA) approved Tibsovo (ivosidenib) for adult patients with relapsed or refractory MDS harboring an isocitrate dehydrogenase-1 (IDH1) mutation. This marks the first targeted therapy approved for this specific MDS subtype. The approval was accompanied by the authorization of the Abbott RealTime IDH1 Assay as a companion diagnostic to identify eligible patients. 
2. Approval of Imetelstat (RYTELO): In June 2024, the FDA approved imetelstat (commercially known as RYTELO) for certain patients with MDS. This approval was based on the results of the IMerge Phase III trial, which demonstrated the efficacy of imetelstat in treating MDS. 
3. Oral Combination Therapy – Inqovi: In July 2020, the FDA approved Inqovi, a combination of decitabine and cedazuridine, for the treatment of adult patients with MDS and chronic myelomonocytic leukemia (CMML). This oral therapy allows patients to receive treatment at home, reducing the need for hospital visits. 
4. Erythroid Maturation Agent – Reblozyl: In August 2023, the FDA approved Reblozyl (luspatercept-aamt) for the treatment of anemia in adult patients with very low- to intermediate-risk MDS with ring sideroblasts. Reblozyl is the first erythroid maturation agent approved for this indication, offering a new option for managing anemia in MDS patients. 

These advancements reflect a growing understanding of MDS and a commitment to developing targeted therapies that address specific genetic mutations and disease characteristics. Ongoing research continues to explore novel treatment options, aiming to improve the quality of life and outcomes for individuals affected by MDS.